ReviewFrontiers in endocrinology2022
Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Functional PET imaging of gut microbiota with [European journal of nuclear medicine and molecular imaging · 2026Article
- Liraglutide and Dapagliflozin Synergistically Reshape Gut Microbiota and Metabolic Profiles to Ameliorate Type‑2 Diabetes in Mice.ACS omega · 2026Article
- Gut microbiota dysbiosis-induced chronic inflammation as a driver of atherosclerosis: cellular crosstalk and host-microbe interactions.Frontiers in cellular and infection microbiology · 2026Review
- Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- The Role of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in Improving Type 2 Diabetes Through Modulation of Gut Microbiota and Metabolites.Obesity surgery · 2026Review
- Dapagliflozin enhances gut barrier function in rats with chronic myocardial infarction by modulating gut microbiota balance.Annals of translational medicine · 2025Article
- Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications.Pharmaceutics · 2025Review
- Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes.Clinical kidney journal · 2025Review
- Unveiling the gut-kidney dialogue in diabetic kidney disease.World journal of diabetes · 2025Article
- Type 2 Diabetes and the Multifaceted Gut-X Axes.Nutrients · 2025Review
- Intestinal Microbiota Composition in Patients with Type 2 Diabetes and Effects of Oral Antidiabetics.Journal of clinical medicine · 2025Article
- Future horizons in diabetes treatment: hypoglycemic activity of [1,2,4]triazino[2,3-Frontiers in endocrinology · 2025Article
- The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications-2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum.Diabetes care · 2024Review
- The gut microbiota and diabetes: research, translation, and clinical applications - 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum.Diabetologia · 2024Review
- Review
- mTOR and SGLT-2 Inhibitors: Their Synergistic Effect on Age-Related Processes.International journal of molecular sciences · 2024Review
- Comparative Binding Study of Gliptins to Bacterial DPP4-like Enzymes for the Treatment of Type 2 Diabetes Mellitus (T2DM).International journal of molecular sciences · 2024Article
- Advancements in precision medicine: multi-omics approach for tailored metformin treatment in type 2 diabetes.Frontiers in pharmacology · 2024Review
- Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter 2 Inhibitor Therapy.Journal of clinical medicine · 2023Review
- Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial.Cardiovascular diabetology · 2023 · on this mapArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current research and existing facts indicate that type 2 diabetes mellitus (T2DM) is characterized by gut microbiota dysbiosis and disturbed microbial metabolites. Oral glucose-lowering drugs are reported with pleiotropic beneficial effects, including not only a decrease in glucose level but also weight loss, antihypertension, anti-inflammation, and cardiovascular protection, but the underlying mechanisms are still not clear. Evidence can be found showing that oral glucose-lowering drugs might modify the gut microbiome and thereby alter gastrointestinal metabolites to improve host health. Although the connections among gut microbial communities, microbial metabolites, and T2DM are complex, figuring out how antidiabetic agents shape the gut microbiome is vital for optimizing the treatment, meaningful for the instruction for probiotic therapy and gut microbiota transplantation in T2DM. In this review, we focused on the literatures in gut microbiota and its metabolite profile alterations beneficial from oral antidiabetic drugs, trying to provide implications for future study in the developing field of these drugs, such as combination therapies, pre- and probiotics intervention in T2DM, and subjects with pregestational diabetes and gestational diabetes mellitus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.